Cargando…
Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia
Autores principales: | Cummins, K D, Jane, S M, Nikovic, S, Bazargan, A, Filshie, R, Sutrave, G, Hertzberg, M, Scott, A, Lane, S, Yannakou, C K, Ritchie, D, D'Rozario, J, Black, J, Bavishi, K, Wei, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219469/ https://www.ncbi.nlm.nih.gov/pubmed/25105536 http://dx.doi.org/10.1038/bcj.2014.59 |
Ejemplares similares
-
Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia
por: Cummins, K D, et al.
Publicado: (2014) -
getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019) -
Leukoreductive response to the combination of sorafenib and chemotherapy in hyperleukocytosis of FLT3-ITD mutated pediatric AML
por: Schmidt, Franziska, et al.
Publicado: (2022) -
Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML
por: Wang, Aoli, et al.
Publicado: (2016) -
Melatonin enhances sorafenib-induced cytotoxicity in FLT3-ITD acute myeloid leukemia cells by redox modification
por: Tian, Tian, et al.
Publicado: (2019)